Reply to ‘Cutaneous adverse effects of the available COVID‐19 vaccines in India: A questionnaire‐based study’ by Bawane J et al.

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence

“…Furthermore, data from real-life settings are important also in patients affected by infections, such as patients affected by latent tuberculosis, as well as patients affected by COVID-19. [60][61][62][63][64][65][66][67][68] Indeed, these conditions may raise several safety concerns during the treatment decision progress. Hence, real-life studies may represent an important source of data to improve the decision-making progress, leading physicians to choose the best treatment for the best patient.…”

Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics

“… 1 Among these, vaccination is the main weapon to overcome the pandemic. 2 Currently, two viral vector‐based vaccines Ad26.COV2.S (Johnson & Johnson) and AZD1222 (AstraZeneca) and two mRNA vaccines [mRNA‐1273 (Moderna) BNT162b2 (Pfizer/BioNTech)] have been authorized by the Italian Medicines Agency. 2 The possible impaired efficacy of vaccines in patients with psoriasis under immunosuppressive/immunomodulant treatment is being widely debated.…”

“… 2 Currently, two viral vector‐based vaccines Ad26.COV2.S (Johnson & Johnson) and AZD1222 (AstraZeneca) and two mRNA vaccines [mRNA‐1273 (Moderna) BNT162b2 (Pfizer/BioNTech)] have been authorized by the Italian Medicines Agency. 2 The possible impaired efficacy of vaccines in patients with psoriasis under immunosuppressive/immunomodulant treatment is being widely debated. In this context, we read with great interest the article recently published in Clinical and Experimental Dermatology by Marovt et al ., 3 which showed that antibody response against COVID‐19 following two doses of BNT162b2 vaccine in patients with psoriasis undergoing biologic treatment did not differ significantly from that of healthy controls in terms of seroconversion.…”

Skin reaction after SARS‐CoV‐2 vaccines Reply to ‘cutaneous adverse reactions following SARS‐CoV‐2 vaccine booster dose: A real‐life multicentre experience’

“…In line with the authors' statement, we conducted a retrospective study including all data collected from patients who attended our Dermatology Department for the onset of skin manifestations related to Covid‐19 vaccination. 2 …”